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The estimated incidence of acute leukemia in pregnancy is 1 in 75 000 pregnancies1 with acute myeloid leukemia (AML) being comt
moner than acute lymphoblastic leukemia (ALL), the 
former accounting for more than twotthirds of cases.1 
About 75% of the cases are diagnosed during the sect
ond and third trimesters.1 Mixed lineage leukemia 
(MLL) gene rearrangement is the dominant genetic 
anomaly in infantile acute leukemia, observed in up 
to 85% of cases.2 This genetic aberration is less fret
quent in adult ALL cases3 and its incidence in mat
ternal leukemia occurring during pregnancy has not 
been reported. 
PATIENTS AND METHODS 
We retrospectively reviewed our institution’s database 
to identify all cases of acute and chronic leukemia 
diagnosed during pregnancy. Thirtytone cases were 
identified, out of which 5 were cases of ALL. Of the 
remaining cases, 15 were AML and 11 CML. Three 
of 5 ALL cases had translocation (4;11) (q21, p23) 
indicative of the MLL gene rearrangement. A summat
ry of the cases is outlined below and listed in Table 1.
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acute lymphoblastic leukemia (all) is a relatively rare disease during pregnancy, accounting for about 
15% of all cases of pregnancy-associated leukemia. although mixed lineage leukemia gene (mll) rear-
rangement is the dominant genetic aberration in infantile acute leukemia, the occurrence of mll gene 
rearrangement in maternal all occurring during pregnancy has not been reported. out of 31 cases of 
maternal leukemia diagnosed during pregnancy at our institution, 5 were all cases. three of the 5 pa-
tients had mll gene rearrangement. the data for these 5 patients are presented in this report. We believe 
that the association of mll gene rearrangement with maternal leukemia is biologically plausible and this 
observation needs to be validated in a larger cohort of pregnancy-associated maternal leukemia cases.
CASE 1 
A 25tyeartold woman, 14 weeks pregnant, was referred 
to our hospital after 2 weeks of fever, easy fatigue, and 
dizziness. She had pallor, purpuric eruption and modert
ate hepatosplenomegaly. The white blood cell count was 
239×109/L with 42% circulating blasts. Bone marrow 
aspiration and biopsy and immunophenotyping were 
consistent with precursortB ALL. Cytogenetics cont
firmed the presence of t(4;11)(q21,q23). Shortly after 
hospitalization she had a spontaneous abortion. She ret
ceived a fourtdrug induction regimen (vincristine, dexat
methasone, idarubicine and asparaginase) and achieved 
a short remission followed by leukemia recurrence. Her 
leukemia was refractory to salvage with hightdose Arat
C (cytarabine). The patient declined further aggressive 
therapy. She was provided with supportive care and 
palliative vincristine and dexamethasone and died 3 
months later.
CASE 2 
A 37tyeartold woman, 29 weeks pregnant, was referred 
with fever, hepatosplenomegaly, lymphadenopathy and 
a white blood cell count of 314×109/L. Her bone mart
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row was infiltrated by blasts expressing a precursortB 
ALL phenotype. Cytogenetics confirmed the presence 
of t(4;11)(q21,q23). After receiving a successful induct
tion with a fourtdrug regimen (vincristine, dexamethat
sone, idarubicine and asparaginase), she had a normal 
delivery of a healthy infant. She received high dose Arat
C consolidation complicated by fungal otitis media. She 
declined stem cell transplantation, preferring to contint
ue on chemotherapy. Three months later she relapsed 
and was refractory to salvage MEC (mitoxantrone, etot
poside and AratC). She was provided with supportive 
care and died 2 months later.
CASE 3 
A 21tyeartold woman, 30 weeks pregnant, presented 
with repeated emesis and weakness during routine 
antenatal followtup. She had generalized adenopathy. 
Her white blood cell count was 10.1×109/L. Her bone 
marrow was infiltrated by blasts expressing a precursor 
Ttcell ALL phenotype. Cytogenetics revealed a normal 
female karyotype. She had induction of labor and gave 
birth to a baby who had anemia of prematurity. After det
livery, she achieved complete remission with induction 
chemotherapy using a fourtdrug regimen (vincristine, 
dexamethasone, idarubicine and asparaginase) followed 
by hightdose AratC and two cycles of CHOD (cyclot
phosphamide, Adriamycin, vincristine and dexamethat
sone) consolidation/intensification. Subsequently she 
was kept on maintenance, but relapsed after being on 
maintenance for 6 months. She was successfully salt
vaged with VCEPtM (vincristine, cyclophosphamide, 
etoposide, prednisone and mitoxantrone) after which 
she had an allogeneic HSCT from her HLAtmatched 
sibling. She experienced another relapse 10 months 
after transplantation. She was provided with palliative 
chemotherapy and supportive care and died 6 months 
later.
CASE 4 
A 41tyeartold woman, 11 weeks pregnant, had a 3t
week history of feeling unwell and of epistaxis. On ext
amination she had pallor, purpura, hepatosplenomegaly 
and lymphadenopathy. Her white blood cell count was 
172×109/L. Her bone marrow showed 82% blast cells 
with a precursortB ALL phenotype. Cytogenetics cont
firmed the presence of t(4;11)(q21,q23). She undert
went a therapeutic abortion, and then achieved comt
plete remission after induction with a fivetdrug regimen 
(cyclophosphamide, vincristine, dexamethasone, idarut
bicine and asparaginase). Shortly after induction she 
had an early relapse that was refractory to fludarabine 
and AratC salvage. She was treated with vincristine and 
dexamethasone and achieved a second complete remist
sion. She subsequently underwent allogeneic HSCT 
from her HLAtmatched sibling. The transplant procet
dure was complicated by reactivation of hepatitis B vit
rus which was successfully treated with lamivudine. She 
remained in complete remission for 3 years, but eventut
Table 1. Three of 5 aLL cases had translocation (4:11) (q21, p23) indicative of the MLL gene rearrangement.
No. Age (y) Gestational age ALL subtype Cytogenetics Pregnancy outcomes Patient outcome
1 25 14 weeks Precursor-B aLL t(4;11) (q21, q23)
Spontaneous 
abortion
Primary refractory. 
died.
2 37 29 weeks Precursor-B aLL t (4;11) (q21, q23)
Full-term 
infant with anemia
Cr with induction. 
relapsed at 3 months 
died.
3 21 30 weeks Precursor       T-cell aLL normal
Full-term 
infant with anemia
Cr with induction 
after delivery. 
relapsed at 6 months. 
allo-SCT in Cr 2. 
relapsed at 10 months 
post SCT. died.
4 41 11 weeks Precursor-B aLL t(4;11) (q21, q23)
Therapeutic 
abortion at 11 weeks
Cr with induction. 
relapse at 2 months. 
allo-SCT in Cr 2. 
relapsed after 3 years. 
died.
5 27 13 weeks Precursor-B aLL non informative
Spontaneous 
abortion  
at 14 weeks.
allo-SCT in Cr 1. 
alive at last  
follow-up at 4 years.
allo-SCT: allogeneic stem cell transplant; Cr 1: First complete remission;  Cr 2: Second complete remission 
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ally presented with extramedullary relapse in the breast 
and CNS. She was given palliative chemoradiotherapy 
and intrathecal chemotherapy. She ultimately died after 
14 months as a result of disease progression.
CASE 5
A 27tyeartold woman presented to a local hospital in 
her 13th week of pregnancy. She had a 2tweek hist
tory of fever and cervical swelling. Her blood picture 
showed a macrocytic anemia, leucocytosis of 35×109/L 
with 10% circulating blasts. Bone marrow aspiration 
and biopsy showed 85% blasts with a precursortB ALL 
phenotype. Cytogenetic analysis was nontinformative. 
She had a spontaneous abortion at week 14 during int
duction chemotherapy. She received high dose AratC 
for consolidation followed by 2 years of maintenance. 
She remained in first complete remission until she was 
lost to follow up after 4 years from diagnosis.
DISCuSSION 
The mutual interaction between pregnancy and leuket
mia may be variable. In addition, there are several diagt
nostic and therapeutic challenges that arise due to the 
heterogeneity of the presenting syndrome, therapeutic 
requirements and ethical issues.
Most of the studies that analyzed leukemia during 
pregnancy had reported a higher incidence of AML 
compared to ALL.1,4t6 In our study, 26 of 31 patients had 
myeloid leukemias, while 5 patients had ALL. Three of 
5 patients had spontaneous abortions. Follow up of the 
two live births showed normal development and neither 
of them had either chemotherapytrelated teratogenicity 
or developed leukemia later in life. It is of interest that 3 
of 5 ALL cases had translocation (4; 11)(q21, q23) int
dicative of the MLL gene rearrangement. Although the 
number of cases is small, the presence of t(4;11) in 3 
of the cases is much higher than would be traditionally 
expected in adult ALL.7
The potential pathologic relation of t(4:11) to leut
kemia during pregnancy is biologically plausible given 
that this is the most prevalent leukemia diagnosed in 
infants, and cases of acute leukemia with a t(4;11) have 
been diagnosed in newborns.2 In infantile acute leuket
mia, the intutero origin of the MLL anomaly has been 
confirmed by retrospective analysis of neonatal blood 
spots (Guthrie cards) of affected infants.8 The high cont
cordance rate for this subtype of leukemia in monozyt
gotic twins of this age and the very short latency further 
supports the above conclusion.9
Pregnancytassociated genetic and/or environt
mental factors may be involved in the pathogenesis of 
MLL+infantile and pregnancytassociated maternal 
leukemia. Epidemiological studies have suggested that 
maternal exposure to high levels of dietary DNA topoit
somerase 2 inhibitors may contribute to MLL+infant 
leukemia.10t12 A potential contributing factor may be 
the exposure to high level of maternal hormones durt
ing pregnancy; in vitro induction of MLL aberrations 
by estrogens, the association in female infants between 
increasing birth weight and MLL+ leukemia and the 
more frequent association of MLL positivity with fet
male sex in adult ALL suggest a role for estrogen expot
sure in MLL leukemogenesis.13t15 
Pregnancy may offer a valuable window of invest
tigation to help elucidate the possible environmental 
and hormonal influences on MLL+ leukemogenesis. 
Certainly further studies to examine the epidemiologic, 
biologic and molecular mechanisms possibly contributt
ing to the potential association between pregnancy and 
maternal and infant MLL+ leukemia would be wart
ranted, and our observations would need to be validatt
ed in a larger cohort of pregnancytassociated maternal 
leukemia, perhaps through a review of one of the larger 
intergroup ALL databases.
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